Plus   Neg

Stock Alert: Mersana Therapeutics Down 6%

Shares of Mersana Therapeutics Inc. (MRSN) are losing more than 6 percent or $1.51 in Tuesday's morning trade at $22.66 despite no company-centric news that could influence the stock.

Cambridge, Massachusetts-based Mersana Therapeutics is a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate or ADC targeting cancers. The company's lead drug candidate is XMT-1536, which is in the expansion portion of a phase I proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma.

Mersana Therapeutics has traded in a range of $1.32 to $24.97 in the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) has gone ahead with the approval of antiviral drug remdesivir as first treatment for COVID-19, notwithstanding last week's findings by the World Health Organization (WHO) that the drug is not effective for COVID-19 treatment. Thursday, Gilead Sciences announced that the FDA approved remdesivir, sold under the brand name Veklury. Integrated payments firm American Express Co. (AXP) reported Friday that net income for the third quarter declined to $1.1 billion or $1.30 per share from $1.8 billion or $2.08 per share in the prior-year quarter. Consolidated total revenues, net of interest expense, also decreased 20 percent to $8.8... The Federal Trade Commission or FTC has launched a new fraud reporting platform, using which, consumers can easily report fraud and all other consumer issues directly to the regulator. In a statement, the FTC said its new website, ReportFraud.ftc.gov, will provide a streamlined and user-friendly way to submit reports about scams, frauds, and bad business practices.
Follow RTT